Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Dear Sir / Madam, We would like to inform you that the officials of the Company will be meeting Investors/Analysts (Participants) as per the details below. Day & Date: Thursday, June 01, 2023. Type of Interaction: In-person Meeting. Host: B&K Conference. Further, discussions will be based on publicly available information. Kindly note that changes may happen due to exigencies on the part of the Participants / Host / Company.
31-05-2023
Bigul

Metropolis Healthcare Ltd - 542650 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Sub: Annual Secretarial Compliance Report of the Company for the financial year ended March 31, 2023 Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI circular No. CIR/CFD/CMD1/27/2019 dated February 8, 2019; we are enclosing herewith the Annual Secretarial Compliance Report of the Company for the financial year ended March 31, 2023, issued by M/s. RM Shah & Co., Practicing Company Secretaries. Request you to kindly take the above information on record and oblige.
29-05-2023
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Dear Sir/ Madam, This is in continuation to our letter bearing Reference No. MHL/Sec&Legal/2023-24/08 dated May 11, 2023. Please find enclosed herewith the transcript of the Q4/FY 22-23 Conference Call (i.e. Post Earnings/Quarterly Call), as organized by Axis Capital Limited on Wednesday, May 17, 2023, at 9:00 a.m. (IST) wherein the financial results of the Company for the quarter ended March 31, 2023, were discussed. The same has also been uploaded on the Company's website, which can be accessed at www.metropolisindia.com. We request you to kindly take the above information on record.
24-05-2023

Buy Metropolis Healthcare; target of Rs 1520: YES Securities

 YES Securities is bullish on Metropolis Healthcare has recommended buy rating on the stock with a target price of Rs 1520 in its research report dated May 17, 2023.
19-05-2023
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 This is to inform you that the Board of Directors of the Company in their meeting held on Tuesday, May 16, 2023 have approved the Audited Standalone and Consolidated Financial Statements of the Company for the quarter and financial year ended March 31, 2023. In this regard and pursuant to the provisions of Regulation 47 of Listing Regulations, 2015 we herewith enclose copy of the Newspaper Advertisement dated May 18, 2023 published in the following Newspapers: 1. Free Press Journal (English); 2. Navshakti (Marathi). This is for your information and record.
18-05-2023
Bigul

Q4FY23 Quarterly & FY23 Annual Result Announced for Metropolis Healthcare Ltd.

 Metropolis Healthcare announced Q4FY23 & FY23 results: Core Business Revenue (Excl. Covid & Covid Allied, PPP Contract & Hi-tech) growth stood at Rs 245 crore up 15% for Q4FY23 & 15% for FY23 on YoY basis Profit after Tax at Rs 33.5 crore Core Business Volume growth for Q4FY23 stood at 15% & 13% for FY23 on YoY basis EBIDTA before Network Expansion for Q4FY23 stood 26.9% Premium Wellness segments grew by 43% for Q4FY23 & by 45% for FY23 indicating strong Brand Equity Consumer’s Trust on Metropolis Brand. Contribution of premium wellness stood at 15% of the non-covid revenues Non-Covid Revenue from North grew by ~30% for Q4FY23 on YoY basis B2C revenue growth for Q4FY23 in Mumbai grew by 18% & Pune grew 23% on account of our strong brand presence & dense network B2C revenue for Q4FY23 in other cities grew by 30% indicating our strong execution & penetration in the newer geographies “Our Core business revenue grew by 15% for Q4FY23 & FY23 on YoY basis. We have been witnessing continuous uptick in our core business revenues over the last 4 quarters with volumes growing across markets. Our revenues from North grew by ~30% for Q4FY23 strengthening our presence in non-core geographies & expanding our reach on Pan-India basis. Revenue contribution from our premium wellness segment increased to 15% in Q4FY23 & witnessed a healthy growth of 43% YoY, a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers. Going forward, we focus on our network expansion, growing our specialised & wellness segments and upgrading our IT infrastructure for enhancing the consumer experience. We believe Metropolis is rightly placed to attain higher market share across geographies & outperform the industry growth." Commented Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd Result PDF
18-05-2023

Metropolis Healthcare Results Earnings Call for Q4FY23

 Conference Call with Metropolis Healthcare Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
17-05-2023

AI cannot replace human knowledge: Metropolis Healthcare Promoter & MD

 In 2021-22, Covid19 business was almost 20-22% of the revenue for most diagnostic companies. The non-Covid19 business is not going to grow by 22% to make it equal
17-05-2023
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 This is in continuation to our letter bearing reference No: MHL/Sec&Legal/2023-24/08 dated May 11, 2023, with respect to intimation of Earnings Call for the quarter ended March 31, 2023 and pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015. The audio recording of the Earnings call held today i.e. on Wednesday, May 17, 2023 at 09:00 am (IST) to discuss the Financials Results of Q4FY23 of the Company, is available on the Company's website under the below link: https://www.metropolisindia.com/newdata/Investors/Submission-to-Stock-Exchange/2022-23/Q4/Metropolis%20-%20Q4FY23%20Earnings%20Call%20Audio.mp3 We request you to kindly take the above on record.
17-05-2023
Bigul

Metropolis Healthcare Ltd - 542650 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('LODR')

 In continuation to our letter Ref: MHL/Sec&Legal/2023-24/13 dated May 16, 2023, it is further informed that as per the requirement of Circular No. LIST/COMP/74/2018-19 dated June 20, 2018 w.r.t. Enforcement of SEBI orders regarding Appointment of Directors by Listed Companies, we hereby affirm that Mr. Sanjay Bhatnagar (DIN: 00867848) and Mr. Vivek Gambhir (DIN: 06527810) who were re-appointed as Non-Executive Independent Directors by the Board in its Meeting held on May 16, 2023 for a second term of 5 years, subject to the approval of Shareholders, are not debarred from holding the office as Director by virtue of any SEBI order or any other such authority. You are requested to kindly take the same on record.
17-05-2023
Next Page
Close

Let's Open Free Demat Account